ASP 7657
Alternative Names: ASP-7657Latest Information Update: 02 Jul 2015
At a glance
- Originator Astellas Pharma
- Class Analgesics; Anti-inflammatories
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Diabetic neuropathies
Most Recent Events
- 31 May 2015 Discontinued - Phase-I for Diabetic neuropathies (In volunteers) in United Kingdom (PO)
- 26 Mar 2015 Astellas Pharma terminates a phase I trial in Diabetic nephropathies (In volunteers) in United Kingdom (NCT02108548)
- 01 Apr 2014 Phase-I clinical trials in Diabetic nephropathies (in volunteers) in United Kingdom (PO)